Sign in
CompletedPhase 2

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Key facts

Who runs it
Microbion Corporation
Where
Dallas, Fresno, McAllen, and San Antonio, United StatesSee the 7 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
47 people enrolled
Started
13 Jun 2022
Ended
19 Jan 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Topical Pravibismane
  • Standard of Care
Record updated
4 November 2024

Who can take part

Age
18 years to 79 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria
  • Has a skin ulcer located on or distal to the malleolus that is ≥ 4 weeks that is clinically documented, and presents with clinical manifestations of a moderate infection (i.e. erythema extending ≥ 2.0 cm from the wound margin), and not requiring hospitalization
  • Has received no more than 36 hours of antibiotic therapy for the moderately infected ulcer prior to enrollment or there is clinical and/or microbiological evidence of failure of antibiotic treatment for the treatment of the moderately infected ulcer
  • Has documented adequate arterial perfusion in the affected limb by biphasic or triphasic Doppler wave forms, a toe brachial index (TBI) ≥0.75, or an ankle brachial index (ABI) of >0.9)
  • Has read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained

Who cannot take part

  • Has more than one concurrent, infected, diabetic foot wound on the study limb
  • Plans to receive treatment with larvae (maggots) for their infected DFU at any time from enrollment through the EOS visit
  • Any condition that has required treatment with any other bismuth containing compound within 2 weeks prior to enrollment through EOS visit (i.e., Kaopectate or Pepto-Bismol, including topical applications such as Xeroform)
  • Plans to receive treatment with Hyperbaric oxygen therapy (HBOT) or topical negative pressure wound therapy (NPWT) for their infected DFU at any time from enrollment through the EOS visit
  • Will undergo a planned surgical therapy beyond standard bedside debridement or incision and drainage, to treat the DFI after enrollment
  • Active alcohol abuse (> 14 drinks per week over the last 3 months) or substance abuse (current use of cocaine, heroin, or methamphetamines) or if drug or alcohol use will interfere with visits in clinic in the opinion of the investigator
  • Has an ulcer due to Charcot arthropathy
  • Has an untreated, uncontrolled, or poorly managed immunosuppressive and or autoimmune disorder
  • Plans to use any topical antibiotics, herbals remedies (e.g., honey), alternative medicines or antimicrobials, either directly or by dressings on their infected DFU at any time from enrollment through the EOS visit
  • History of major medical noncompliance
  • End stage renal disease requiring dialysis
  • Has a known allergy to bismuth and/or MBN-101 excipients (methylcellulose, Tween 80 (polysorbate 80))
  • Is immunocompromised and not well-managed due to illness [human immunodeficiency virus (HIV), autoimmune disease] or organ transplant
  • Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures
  • Has other medical condition(s) which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results
  • Plans to receive treatment with advanced cellular therapies (e.g., Platelet-derived growth factor (PDGF), Cellular Tissue Products (CTP), granulocyte colony-stimulating factor (G CSF)) for their infected DFU at any time from enrollment through the EOS visit
  • Glycated hemoglobin >12%
  • Has a serum creatinine, ALT, AST or Alkaline Phosphatase >3 times the upper limit of the normal range of the local testing laboratory
  • Has an absolute neutrophil count <1000
  • Has a history of any type of cancer (excluding non-melanoma localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix) unless the subject has been free of cancer for > 5 years
  • Has proven or highly suspected, involvement of bone (i.e., osteomyelitis)
  • Is unwilling or unable to attend clinic visits and keep research appointments
  • Is unwilling or unable to adhere to the systemic antibiotic treatment prescribed
  • Is unwilling or unable to adhere to proper pressure off-loading of the foot wound (when needed) from enrollment through EOS as directed by the treating physician
  • Has participated in an investigational trial to evaluate pharmaceuticals or biologics either concurrently or within the past 30 days

Where in United States

  • Parkland Comprehensive Wound CenterDallas, United States
  • Parkland Memorial HospitalDallas, United States
  • University of Texas Southwestern Medical Center - William P. Clements, Jr., University HospitalDallas, United States
  • University of Texas Southwestern Medical Center University Wound Care ClinicDallas, United States
  • Limb Preservation Platform IncFresno, United States
  • Futuro Clinical Trials, LLCMcAllen, United States
  • Bio-X-Cell ResearchSan Antonio, United States

About the trial

What the trial wants to find out

This is a randomized, open label, controlled, multi-center study to assess safety, tolerability, and efficacy of adjunctive treatment with topically applied pravibismane (MBN-101) in patients with moderate diabetic foot infections. Patients will be randomized in a 2:1 ratio (MBN-101:standard of care). Topical pravibismane (MBN-101) will be applied three times per week for up to 12 weeks. All patients will receive systemic antibiotic treatment for a least a portion of that period. Randomization will be stratified by site.

The 2 groups in the trial

  • Topical Pravibismane (MBN-101)Treatment being tested

    Topical pravibismane (MBN-101) at a dose of 2.5 mg/mL will be applied directly to the infected wound and covered with an appropriate non-antimicrobial dressing. Dosing will occur 3 times per week for the 12 weeks of treatment.

    Treatment: Topical Pravibismane

  • Standard of CareOther group

    Standard of care treatment without administration of any topical drugs.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open Label, Controlled, Phase 2, Multi-Center Study to Assess Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 (Pravibismane Topical Suspension) in Subjects With Moderate Diabetic Foot Infection (DFI)
Record updated
4 November 2024